Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

by @JTC_PALIdev | Apr 16, 2024 | Press Releases

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a...

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

by @JTC_PALIdev | Apr 11, 2024 | Press Releases

– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a...

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

by @JTC_PALIdev | Apr 10, 2024 | Press Releases

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade...

Palisade Bio Announces 1-for-15 Reverse Stock Split

by @JTC_PALIdev | Apr 3, 2024 | Press Releases

Carlsbad, CA, April 03, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

by @JTC_PALIdev | Mar 27, 2024 | Press Releases

– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical Advisory Board – Sufficient cash on hand to execute on...

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

by @JTC_PALIdev | Feb 15, 2024 | Press Releases

Carlsbad, CA, Feb. 15, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that...